This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rectiv

Allergan plc

Drug Names(s): 0.4% nitroglycerin ointment, Cellegesic, Rectogesic

Description: Cellegesic is a nitroglycerin ointment. Nitroglycerin is converted in the body by aldehyde dehydrogenase to nitric oxide, which causes smooth muscle relaxation through activation of guanylate cyclase. This reduces sphincter tone and resting intra-anal pressure.

Deal Structure: Cellegy and ProStrakan
In November 2006, Cellegy renegotiated the EU License and Distribution Agreement for Cellegesic (Rectogesic in Europe) with ProStrakan Group. Under the terms of the amended agreement, ProStrakan will assume responsibility for all manufacturing and other product support functions and will purchase the product directly from the manufacturer rather than purchasing from Cellegy under the terms of the original agreement. In return, Cellegy will receive a payment of $2 million and may receive future milestone payments of up to $750,000.

On November 28, 2006, for an aggregate purchase price of approximately $9.0 million, Cellegy completed the sale to Strakan International Limited, a wholly owned subsidiary of ProStrakan Group, of its rights to Cellegesic, Fortigel, Tostrex, Tostrelle, and related intellectual property assets.

Paladin and ProStrakan
In December 2010, Paladin and ProStrakan entered into a new strategic relationship in...See full deal structure in Biomedtracker

Partners: Kyowa Hakko Kirin Co., Ltd.


Rectiv News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug